Effects of allogeneic mesenchymal stem cell transplantation in the treatment of liver cirrhosis caused by autoimmune diseases.

摘要: Aim There has been great interest in recent years to take advantage of mesenchymal stem cells (MSCs) treat end-stage liver disease. This study is aimed evaluate clinical therapeutic effects allogeneic MSC transplantation cirrhosis caused by autoimmune diseases. Methods The enrolled patients with were assigned receive infusions through a peripheral vein. The primary objective this was assess the safety and effectiveness MSCT diseases-induced cirrhosis. Secondary endpoints changes Models End Stage Liver Disease (MELD) scores functions after transplantation. Results A total 26 enrolled. Of these, 23 received umbilical cord MSCT, two blood one bone marrow MSCT. Three patents died complications Four lost follow-up. mean alanine transaminase values decreased 6 months, 1 2 transplantation, but there no statistical significance. value bilirubin at months year Average serum albumin levels improved increased significantly compared baseline value. A lowering prothrombin time seen MELD score No serious adverse events observed during or 24 h MSCs any cirrhosis. Conclusion Based on trial, vein probably safe seemingly beneficial effect Therefore, potential option for treatment diseases. Further studies higher numbers are warranted better clarify impact mechanisms